



CUMULATIVE ANTIMICROBIAL SUSCEPTIBILITY REPORT

January 1, 2024 - December 31, 2024

Prepared by T. Canonica, PharmD and C. Lee PharmD, BCPS
Antimicrobial Stewardship Program Manager

Please note the following comments:

- All data is reported as percent fully susceptible
- First isolate per patient per organism is counted in the antibiogram
- 30 organisms are required to report susceptibilities on an antibiogram per CLSI guidelines. Some organisms were included in despite less than 30 organisms isolated
- When treating UTIs caused by *E. Coli*, *Klebsiella spp.*, and *Proteus spp.*, cefazolin can be used to predict results for the following oral agents: cephalexin (Keflex) and cefpodoxime (Vantin)
- Gentamicin susceptibilities for *Enterococcus spp.* are for gram-positive synergy
- Non-urine coagulase-negative *Staphylococcus* includes: *S. auricularis*, *S. capitis*, *S. haemolyticus*, *S. hominis*, *S. lugdunensis*, *S. simulans*, *S. ureilyticus*, *S. warneri*
- Urine coagulase-negative *Staphylococcus* includes: *S. epidermidis*, *S. haemolyticus*, *S. lugdunensis*, and *S. warneri*
- Key: ESBL: Extended-spectrum beta-lactamase; CR: Carbapenem resistant; VRE: Vancomycin resistant enterococci; MR: Methicillin resistant; NA: Not available; R: Intrinsically resistant

Urine Culture Antibiogram

	# Isolates	Amoxicillin/ clavulanate	Ampicillin	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Ertapenem	Levofloxacin	Nitrofurantoin	Sulfamethoxazole/ trimethoprim	Oxacillin	Vancomycin
Gram negative													
<i>Enterobacter cloacae</i> complex	45	R	R	R	96	R	89	96	89	60	87	R	R
<i>Escherichia coli</i> (ESBL 15%)	442	83	45	81	84	84	70	100	64	99	69	R	R
<i>Klebsiella oxytoca</i> (ESBL 7%)	30	97	R	90	93	90	100	100	100	87	97	R	R
<i>Klebsiella pneumoniae</i> (ESBL 13%)	142	94	R	85	86	85	84	100	80	49	79	R	R
<i>Proteus mirabilis</i> (CR 1%)	89	88	73	73	74	73	72	99	71	R	64	R	R
<i>Pseudomonas aeruginosa</i> (CR 15%)	67	R	R	R	82	R	83	R	73	R	R	R	R
Gram positive													
<i>Enterococcus faecalis</i> (VRE 0%)	108	100	100	R	R	R	R	R	NA	100	R	NA	100
<i>Staphylococcus aureus</i> (MRSA 39%)	44	NA	R	61	NA	NA	R	R	NA	100	84	61	100
Coagulase-negative <i>staphylococcus</i>	201	NA	R	54	NA	NA	R	R	NA	99	69	54	100



Non-Urine Culture Antibigram

	# Isolates	Ampicillin	Cefazolin	Ceftriaxone	Ertapenem	Piperacillin/ tazobactam	Cefepime	Ciprofloxacin	Levofloxacin	Gentamicin	Oxacillin	Sulfamethoxazole/ trimethoprim	Clindamycin	Doxycycline	Vancomycin	Linezolid	Daptomycin
Gram negative																	
<i>Escherichia coli</i> (ESBL 12%)	67	55	NA	81	100	94	81	70	69	90	R	NA	R	R	R	R	R
<i>Klebsiella pneumoniae</i> (ESBL 19%)	27	R	NA	89	100	96	89	89	85	100	R	NA	R	R	R	R	R
<i>Proteus mirabilis</i>	26	73	NA	73	100	100	73	69	86	95	R	73	R	R	R	R	R
<i>Pseudomonas aeruginosa</i> (CR 11%)	44	R	R	R	R	88	93	84	79	R	R	R	R	R	R	R	R
Gram positive																	
<i>Enterococcus faecalis</i>	72	100	R	R	R	100	R	NA	NA	82	NA	R	R	NA	99	100	100
<i>Staphylococcus aureus</i>	228	R	70	NA	NA	NA	NA	NA	NA	R	70	94	79	96	100	100	100
MSSA (70%)	159	R	100	NA	NA	NA	NA	NA	NA	R	100	97	81	96	100	100	100
MRSA (30%)	69	R	R	NA	NA	NA	NA	NA	NA	R	R	87	74	97	100	100	100
Coagulase-negative staph (MR 52%)	83	R	48	NA	NA	NA	NA	NA	NA	R	48	68	59	86	99	100	100
<i>Staphylococcus epidermitis</i> (MR 44%)	34	R	56	NA	NA	NA	NA	NA	NA	R	56	57	57	83	98	100	100